Figure 1From: Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient populationRemission rates at the end point (12 months) in the risperidone (long-acting, injectable) (RLAI) and control groups (last observation carried forward used for missing data).Back to article page